298 related articles for article (PubMed ID: 23922022)
1. Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression.
Nishino M; Dahlberg SE; Cardarella S; Jackman DM; Rabin MS; Ramaiya NH; Hatabu H; Jänne PA; Johnson BE
Cancer; 2013 Nov; 119(21):3761-8. PubMed ID: 23922022
[TBL] [Abstract][Full Text] [Related]
2. Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.
Nishino M; Dahlberg SE; Fulton LE; Digumarthy SR; Hatabu H; Johnson BE; Sequist LV
Acad Radiol; 2016 Mar; 23(3):329-36. PubMed ID: 26776293
[TBL] [Abstract][Full Text] [Related]
3. Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.
Lee JH; Lee HY; Ahn MJ; Park K; Ahn JS; Sun JM; Lee KS
Cancer Imaging; 2016 Mar; 16():5. PubMed ID: 26984681
[TBL] [Abstract][Full Text] [Related]
4. Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI.
Nishino M; Dahlberg SE; Cardarella S; Jackman DM; Rabin MS; Hatabu H; Jänne PA; Johnson BE
J Thorac Oncol; 2013 Aug; 8(8):1059-68. PubMed ID: 23787800
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Aiko N; Shimokawa T; Miyazaki K; Misumi Y; Agemi Y; Ishii M; Nakamura Y; Yamanaka T; Okamoto H
BMC Cancer; 2018 Oct; 18(1):1012. PubMed ID: 30348116
[TBL] [Abstract][Full Text] [Related]
6. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.
Heon S; Yeap BY; Lindeman NI; Joshi VA; Butaney M; Britt GJ; Costa DB; Rabin MS; Jackman DM; Johnson BE
Clin Cancer Res; 2012 Aug; 18(16):4406-14. PubMed ID: 22733536
[TBL] [Abstract][Full Text] [Related]
7. Tumor Growth Rate After Nadir Is Associated With Survival in Patients With
Nishino M; Lu J; Hino T; Vokes NI; Jänne PA; Hatabu H; Johnson BE
JCO Precis Oncol; 2021 Nov; 5():1603-1610. PubMed ID: 34994646
[TBL] [Abstract][Full Text] [Related]
8. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
Yoshida T; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y; Goto K
Lung Cancer; 2015 Dec; 90(3):477-83. PubMed ID: 26604031
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
10. Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors.
Nishino M; Cardarella S; Dahlberg SE; Jackman DM; Ramaiya NH; Hatabu H; Rabin MS; Jänne PA; Johnson BE
Lung Cancer; 2013 Mar; 79(3):283-8. PubMed ID: 23254265
[TBL] [Abstract][Full Text] [Related]
11. RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.
Nishino M; Cardarella S; Jackman DM; Ramaiya NH; Rabin MS; Hatabu H; Jänne PA; Johnson BE
AJR Am J Roentgenol; 2013 Jul; 201(1):W64-71. PubMed ID: 23789698
[TBL] [Abstract][Full Text] [Related]
12. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
[TBL] [Abstract][Full Text] [Related]
13. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
Li J; Qu L; Wei X; Gao H; Wang W; Qin H; Tang C; Guo W; Wang H; Liu X
Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337
[TBL] [Abstract][Full Text] [Related]
14. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
15. Tumor shrinkage rate as a potential marker for the prediction of long-term outcome in advanced non-small cell lung cancer treated with first-line tyrosine kinase inhibitors.
Yu S; Wang X; Wang X; Wu X; Xu R; Wang X; Zhang X; Zhang C; Chen K; Cheng D; Wenfeng L
J Cancer Res Ther; 2019; 15(7):1574-1580. PubMed ID: 31939440
[TBL] [Abstract][Full Text] [Related]
16. Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Imai H; Kaira K; Mori K; Kotake M; Mitani M; Kawashima N; Hisada T; Minato K
Thorac Cancer; 2019 Dec; 10(12):2200-2208. PubMed ID: 31595714
[TBL] [Abstract][Full Text] [Related]
17. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
18. Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study.
Kashiwabara K; Fujii S; Tsumura S; Sakamoto K
J Cancer Res Clin Oncol; 2021 Jan; 147(1):287-293. PubMed ID: 32761377
[TBL] [Abstract][Full Text] [Related]
19. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.
Jackman DM; Miller VA; Cioffredi LA; Yeap BY; Jänne PA; Riely GJ; Ruiz MG; Giaccone G; Sequist LV; Johnson BE
Clin Cancer Res; 2009 Aug; 15(16):5267-73. PubMed ID: 19671843
[TBL] [Abstract][Full Text] [Related]
20. Prediction Model for Tumor Volume Nadir in EGFR -mutant NSCLC Patients Treated With EGFR Tyrosine Kinase Inhibitors.
Nishino M; Lu J; Hino T; Vokes NI; Jänne PA; Hatabu H; Johnson BE
J Thorac Imaging; 2023 Mar; 38(2):82-87. PubMed ID: 34524205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
